Webcasted presentation to take place at 1:10pm ETDENVER, CO / ACCESSWIRE / November 30, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference on December 7, 2023.Mr. Disbrow will conduct a presentation and subsequently open the floor to questions. Please submit your questions in advance to [email protected]'s presentation will be on Thursday, December 7th at 1:10pm ET. To register to stream the presentation live, visit this LINK or visit the Company's website.If attendees are not able to
ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced that Mark Oki will join Aytu as the company's chief financial officer effective January 17, 2022. Mr. Oki will serve as a member of Aytu's executive committee and will report to Josh Disbrow, chief executive officer. Mr. Oki will provide leadership and oversight of the company's financial operations and planning, accounting, information technology and select other functions."On behalf of the entire company, I am delighted to welcome Mark to Aytu and look forward to partnering with him as we
- Closed merger with Neos Therapeutics creating a proforma combined $100 million revenue specialty pharmaceutical company -- Added late-stage pediatric onset rare disease asset, protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) to development pipeline -- Record quarter for consumer health division with revenue reaching $8.4 million and Rx division revenue up 9% over same quarter last year -- Grew leadership team with three executives including CFO, Rich Eisenstadt - - Management to host live conference call and webcast today at 4:30 p.m. ET -ENGLEWOOD, CO / ACCESSWIRE / May 17, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commerciali
DENVER, CO / ACCESSWIRE / August 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will participate in a webcasted presentation and host one-on-one meetings with investors at the Sidoti Micro-Cap Virtual Conference, taking place virtually on Wednesday, August 14, 2024, and Thursday, August 15, 2024.WebcastThe webcasted fireside chat will take place at 12:15 p.m. Eastern time on Thursday, August 15, 2024. The webcast can be accessed by visiting the investor relations section of the Company's website at https://investors.aytubio.com or direct
Consumer Health Wind Down and Sale Maximizes Shareholder Value as Company Focuses on Rx SegmentEliminates Materially All Remaining Expenses Associated with the Consumer Health BusinessProvides for Receipt of Future Sales-Based Royalty Payments DENVER, CO / ACCESSWIRE / August 6, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that following the wind down of operations, it has entered into a definitive agreement to divest its Consumer Health (a/k/a Innovus Pharmaceuticals) business to a private, e-commerce focused company. The divested business encompasses the established e-commerce pl
MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 73rd Emerging Growth Conference on July 17 & 18 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) 485
8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
Cantor Fitzgerald initiated coverage of Aytu BioPharma with a rating of Overweight and set a new price target of $11.00
Q3 2024 ADHD Portfolio net revenue up 49% compared to Q3 2023Q3 2024 adjusted EBITDA 1 improved by $7.0 million compared to Q3 2023TTM March 2024 operating income of $7.3 million for the Rx BusinessTTM March 2024 companywide adjusted EBITDA of positive $15.4 millionTTM March 2024 adjusted EBITDA of positive $17.1 million for the Rx Business$19.8 million cash balance at March 31, 2024Company to host conference call and webcast today, May 15, 2024, at 4:30 p.m. Eastern timeDENVER, CO / ACCESSWIRE / May 15, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results
DENVER, CO / ACCESSWIRE / May 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its third quarter of fiscal 2024 for the period ended March 31, 2024, after the market close on Wednesday, May 15, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, May 15, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.Conference Call DetailsDate and Time: Wednesday, May 15, 2024, at 4:30 p.m. Eastern TimeCall-in Information: Interested parties can access the conference call by di
Q2 2024 operating income of $2.4 millionQ2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 millionQ2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted EBITDA of $5.5 millionQ2 2024 ADHD Portfolio net revenue up 49% compared to Q2 2023$19.5 million cash balance at December 31, 2023Company to host conference call and webcast today, February 14, 2024 at 4:30 p.m. Eastern timeDENVER, CO / ACCESSWIRE / February 14, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 second quarter.Q2 2024 High
SC 13D/A - AYTU BIOPHARMA, INC (0001385818) (Subject)
SC 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)
SC 13D/A - AYTU BIOPHARMA, INC (0001385818) (Subject)
4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.64) by 18.75 percent. This is a 73.06 percent increase over losses of $(1.93) per share from the same period last year. The company reported quarterly sales of $17.993 million which beat the analyst consensus estimate of $17.346 million by 3.73 percent. This is a 20.85 percent decrease over sales of $22.733 million the same period last year.
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.25) by 84 percent. The company reported quarterly sales of $22.93 million which beat the analyst consensus estimate of $21.75 million by 5.47 percent. This is a 12.73 percent decrease over sales of $26.28 million the same period last year.
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is projected to report quarterly earnings at $1.65 per share on revenue of $24.62 billion. • CAE (NYSE:CAE) is estimated to report quarterly earnings at $0.18 per share on revenue of $819.57 million. • CNH Industrial (NYSE:CNHI) is estimated to report quarterly earnings at $0.42 per share on revenue of $6.66 billion. • Great Lakes Dredge & Dock (NASDAQ:GLDD) is estimated to report quarterly earnings at $0.10 per share on revenue of $183.47 million. • Louisiana-Pacific (NYSE:LPX) is likely to report quarterly earnings at $0.55 per share on revenue of $619.97 million. • Martin Marietta Materials (NYSE:MLM) is projected to repor